Recursion Announces Its First Major Multidisciplinary Expansion, in Toronto, to Further Tech-Enabled Drug Discovery
June 15, 2021 at 08:54 am
Share
Recursion announced its intention to soon launch its first major multidisciplinary expansion beyond its Utah headquarters, with plans to hire up to 50 people in Toronto by the end of 2021. Recursion has over 260 employees across biology, chemistry, automation, data science, machine learning, engineering and accelerating functions. Over the past year, Recursion has increased its headcount by over 60 per cent. Through this growth, Recursion lived its values by helping all Recursionauts navigate the pandemic while safely keeping its labs open, secured a transformational discovery partnership with a major biopharmaceutical company and debuted on the public markets, all to accelerate the company's progress toward achieving its mission. Recursion has initiated the office selection process in Toronto and plans to open the doors of its new hub in the fall. This multidisciplinary hub will join its Salt Lake City, Utah headquarters and Milpitas, Californiainvivo biology center. Recursion has partnered with Toronto Global, a team of experienced business advisors assisting businesses around the globe expand into the Toronto Region, and the Canadian Trade Commissioner Service, both of which are supporting Recursion's investment in Toronto and Canada.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.